Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT.


Journal

Human immunology
ISSN: 1879-1166
Titre abrégé: Hum Immunol
Pays: United States
ID NLM: 8010936

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 16 01 2020
revised: 06 03 2020
accepted: 14 03 2020
pubmed: 23 3 2020
medline: 20 2 2021
entrez: 23 3 2020
Statut: ppublish

Résumé

In addition to T cells, NK cells can also participate in the outcome of hematopoietic stem cell transplantation (HSCT) mainly through the interaction between donor killer cell immunoglobulin-like receptors (KIRs) and recipient human leukocyte antigen (HLA) class I molecules. There is a risk of GVHD other than leukemia relapse after allogeneic HSCT that activation of donor NK cells in the absence of appropriate inhibitory ligands will be one of the reasons. To investigate the impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD and leukemia relapse in patients with acute leukemia after HSCT, 100 patients with acute leukemia who received HSCT from their HLA-matched siblings were included in this study. Genotypes of 16 KIR genes and two 2DS4 variants (full length and deleted alleles), along with HLA-A/B genotypes, were determined by PCR-SSP. HLA-C genotyping was done with the SSO-Luminex method. Chimerism analysis was done using 16 short tandem repeats (STRs) to detect early leukemia relapse. Acute (a)GVHD occurred in 38 patients, and 16 of them died during the study. None of the recipients showed any sign of leukemia relapse after HSCT. Full donor chimerism was observed in all tested patients during the first year after HSCT. Our results also indicated an increased risk of aGVHD in AA recipients with the C2/Cx, Bw4

Identifiants

pubmed: 32199702
pii: S0198-8859(20)30039-2
doi: 10.1016/j.humimm.2020.03.004
pii:
doi:

Substances chimiques

HLA Antigens 0
Histocompatibility Antigens Class I 0
Receptors, KIR 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

285-292

Informations de copyright

Copyright © 2020 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Auteurs

Marzieh Mansouri (M)

Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran.

Jean Villard (J)

Immunology and Transplant Unit, National Reference Laboratory for Histocompatibility (LNRH), Geneva, Switzerland.

Mani Ramzi (M)

Hematology and Bone Marrow Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Ali Alavianmehr (A)

Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran.

Shirin Farjadian (S)

Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: farjadsh@sums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH